Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease

  • Authors:
    • Lei Lu
    • Le Tang
    • Wenshi Wei
    • Yunyi Hong
    • Heyu Chen
    • Weihai Ying
    • Shengdi Chen
  • View Affiliations

  • Published online on: July 14, 2014     https://doi.org/10.3892/etm.2014.1842
  • Pages: 943-950
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nicotinamide adenine dinucleotide (NAD+) repletion has been shown to provide marked neuroprotection from genotoxic agent‑induced neuronal and astrocyte cell death. One of the key precursors of NAD+ is nicotinamide mononucleotide (NMN). Therefore, it was hypothesized that NMN may attenuate apoptosis and improve energy metabolism in Parkinson's disease (PD)‑like behavioral and neuropathological changes, and produce significant beneficial effects. In this study, a cellular model of PD, using rotenone‑treated PC12 cells, was established to test the hypothesis that NMN may decrease PD‑like pathological changes. Experiments were carried out to investigate cell survival, including an intracellular lactate dehydrogenase (LDH) assay. Apoptotic and necrotic cell death, NAD+ levels and ATP levels were also evaluated. It was observed that NMN was able to significantly attenuate the rotenone‑induced reduction in the survival rate of PC12 cells, as assessed by MTT and LDH assays. NMN treatment also significantly reduced the rotenone‑induced apoptosis of the cells, as assessed by flow cytometry‑based Annexin V/7‑aminoactinomycin D staining. Furthermore, NMN restored intracellular levels of NAD+ and ATP in the rotenone‑treated cells, thus demonstrating the capacity of NMN to ameliorate mitochondrial inhibitor‑induced impairments of energy metabolism. The present study indicates that NMN produces significant beneficial effects by attenuating apoptosis and improving energy metabolism in a cellular model of PD. These results suggest that NMN may become a promising therapeutic drug for PD.
View Figures
View References

Related Articles

Journal Cover

September-2014
Volume 8 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu L, Tang L, Wei W, Hong Y, Chen H, Ying W and Chen S: Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease. Exp Ther Med 8: 943-950, 2014.
APA
Lu, L., Tang, L., Wei, W., Hong, Y., Chen, H., Ying, W., & Chen, S. (2014). Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease. Experimental and Therapeutic Medicine, 8, 943-950. https://doi.org/10.3892/etm.2014.1842
MLA
Lu, L., Tang, L., Wei, W., Hong, Y., Chen, H., Ying, W., Chen, S."Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease". Experimental and Therapeutic Medicine 8.3 (2014): 943-950.
Chicago
Lu, L., Tang, L., Wei, W., Hong, Y., Chen, H., Ying, W., Chen, S."Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease". Experimental and Therapeutic Medicine 8, no. 3 (2014): 943-950. https://doi.org/10.3892/etm.2014.1842